Antibody responses to inactivated SARS-CoV-2 vaccine in peritoneal dialysis patients.
Semin Dial
; 35(3): 264-268, 2022 05.
Article
in English
| MEDLINE | ID: covidwho-1606773
ABSTRACT
INTRODUCTION:
As end-stage renal disease (ESRD) patients generally have reduced responses to the vaccines, effectiveness of newly developed SARS-CoV-2 vaccines in ESRD are also matters of curiosity. We aimed to investigate the humoral responses of our peritoneal dialysis (PD) patients to the inactivated SARS-CoV-2 vaccine.METHODS:
Humoral immune responses of 23 PD patients who received two doses of the inactivated SARS-CoV-2 vaccine were investigated with a commercial test that measures IgG antibodies towards receptor binding domain of SARS-CoV-2 spike protein. Seropositivity rates, antibody titers, and ESRD related clinical data were compared with 51 hemodialysis (HD) patients and 29 healthy volunteers.RESULTS:
Seropositivity of PD patients with the inactivated vaccine was 95.6%. Both the rate of seropositivity and SARS-CoV-2 IgG antibody levels in PD patients were not different from the healthy controls (p = 0.85 and 0.19, respectively). While seropositivity rates were not different for PD or HD patients (p = 0.09), the magnitude of humoral responses was significantly higher in PD patients (p = 0.0001). There were no vaccine-related serious adverse events. In the 3-months clinical follow-up, none of the patients experienced SARS-CoV-2 infection.CONCLUSION:
Two doses of the inactivated vaccine generate adequate humoral immune response in PD patients without any serious adverse events.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Peritoneal Dialysis
/
COVID-19
/
Kidney Failure, Chronic
Type of study:
Cohort study
/
Prognostic study
Topics:
Vaccines
Limits:
Female
/
Humans
/
Male
Language:
English
Journal:
Semin Dial
Journal subject:
Nephrology
Year:
2022
Document Type:
Article
Affiliation country:
Sdi.13049
Similar
MEDLINE
...
LILACS
LIS